<DOC>
	<DOCNO>NCT00479349</DOCNO>
	<brief_summary>To assess safety tolerability ascend multiple oral dos SAM-531 , investigational drug , healthy Japanese young male elderly subjects.To provide pharmacokinetics ( PK ) pharmacodynamics ( PD ) profile multiple oral dos SAM-531 healthy Japanese young male elderly subject .</brief_summary>
	<brief_title>Study Evaluating Safety , Pharmacokinetics , Pharmacodynamics SAM-531</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion Men age 20 45 year , inclusive , screen . Elderly men woman age 65 year screen . Body mass index ( BMI ) range 17.6 26.4 kg/m2 body weight â‰¥45 kg . Exclusion critereia Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease . Any clinically important deviation normal limit physical examination , vital sign , 12lead ECGs , clinical laboratory test result . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level upper limit normal screening . Tobacco use consumption caffeinecontaining product ( e.g. , coffee , tea , chocolate , carbonate beverage ) alcoholic beverage within 48 hour study day 1 end inpatient confinement period .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>